

Angélique Gougelet, PhD

ORCID number: 0000-0001-7464-9804, Scopus Author ID: 8737049800, H-Index: 13

Born on March 13th, 1980 at Châtenay-Malabry, France

Centre de Recherche des Cordeliers-Umrs1138

15 rue de l'école de médecine, 75006 Paris

01 44 27 60 36

angelique.gougelet@inserm.fr

<https://www.crcordeliers.fr/equipes/oncogenic-functions-of-b-catenin-signaling-in-the-liver/>

ACTUAL POSITION

Co-director of the Team “Oncogenic functions of the beta-catenin in the liver” directed by S. Colnot, “Chargé de Recherche Classe Normale” since october 2015

TRAINING & TEACHING

- Internships of 18 students, 2 PhD students
- Teaching in L3 Pro « Microbiologie Industrielle et Biotechnologies » and M2 MIAC (2011-now) for Université Paris Cité, and M1 “Magistère Européen de Génétique” (2019-now) for Université Paris Cité, and « DIU Médecine moléculaire en cancérologie » (2022) for Université Paris Saclay/SIRIC CARPEM
- Organizer of workshops for the “Fête de la Science” (2016-2018, 2021, 2022, 2023) and for young students from “Envol” association (2016-now)
- Speaker for the DECLICS program (2023)

SCIENTIFIC EXPERTISE

- Member of the scientific Council in UFR927 since 2023
- “Rang B” representative in UFR927 council since 2022
- Member of the “bureau des personnels” in UFR927 since 2022
- Member of the selection committee for abstracts during EASL meeting 2023-2025, during AFEF meeting 2020; 2023
- Member of the organizing committee for seminars in Centre de Recherche des Cordeliers (2019-2023)
- Editorial member of the “World Journal of Hepatology” Journal since April 2018
- Reviewing of more than 100 international manuscripts (*Gut*, *Journal of Hepatology*, *Hepatology*, *Liver International*, *Journal of Clinical Investigation*, *JHep Report*, *International Journal of Hepatology*...)
- Expert for grants from AFEF, National Science Centre Poland, Ligue Nationale contre le Cancer, Telethon Grant in Italy and a grant for the Israel Science Foundation
- Reporter of five theses, ten “Comité de suivi de thèse”, one « Maître de Conférences » recruitment examination
- Speaker in 21 meetings, invited in 7

FUNDINGS

- CARPEM Emergence and Innovation (2023-2024)
- PLBIO21 « Liver resident macrophages: key actors in the pathogenesis of hepatocellular carcinoma” (2022-2025)
- ANR JCJC « β -catenin-mediated epigenetic control of the imprinted DLK1/Dio3 locus in liver” (2018-2021)
- AAP *Association Française d'Etude du Foie* 2018

PRIZE AND DISTINCTIONS

- RIPEC3 INSERM award in 2022
- APEMM Prize for the best manuscript in 2015

- Young investigator Bursaries in EASL 2013 and EASL HCC summit 2014, in AFEF 2013
- Prize of the best talk in the Wnt meeting 2010

MAIN PUBLICATIONS

18 international manuscripts, 11 reviews, 3 book chapters

- J. Sanceau, L.Poupel, C. Joubel, ...Sabineand **Angélique Gougelet**. DLK1/DIO3 locus upregulation by a β -catenin-dependent enhancer drives cell proliferation and liver tumorigenesis, **Molecular therapy**, 2024 Feb 3:S1525-0016(24)00037-6. doi: 10.1016/j.ymthe.2024.01.036.
- Mouillet-Richard S, **Gougelet A***, Passet B*, Brochard C*, ...and Laurent-Puig P. Wnt, glucocorticoid and cellular prion protein cooperate to drive a mesenchymal phenotype with poor prognosis in colon cancer. *J Transl Med.* 2024 Apr 8;22(1):337. doi: 10.1186/s12967-024-05164-0. * equal contribution
- J. Sanceau and **Gougelet A**. Epigenetic mechanisms of liver tumor resistance to immunotherapy. **World J Hepatol.** 2021 Sep 27;13(9):979-1002. doi: 10.4254/wjh.v13.i9.979.
- Loesch R, Caruso S, Paradis V, Godard C, **Gougelet A**, et al. Deleting the β -catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth. *J Hepatol.* 2022 Mar 4:S0168-8278(22)00130-1. doi: 10.1016/j.jhep.2022.02.023.
- M. Cadoux, S. Caruso, S. Pham, **A. Gougelet**, ... and J-P. Couty. Expression of NKG2D ligands is downregulated by β -catenin signalling and associates with HCC aggressiveness. **J.Hepatol.** 2021 Jan 20: S0168-8278(21)00028-3. doi: 10.1016/j.jhep.2021.01.017.
- **A. Gougelet***, C. Sartor*, N. Senni*, ... and S.Colnot. Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography **Gastroenterology.** 2019; 157 (3): 807-822. doi: 10.1053/j.gastro.2019.05.069.
- C. Sartor, ..., **A. Gougelet*** and S. Colnot*. The concomitant loss of APC and HNF4 α in adult hepatocytes does not contribute to hepatocarcinogenesis driven by β -catenin activation. **Liver Int.** 2019; 39 (4): 727-739. doi: 10.1111/liv.14068* AG and SC contributed equally to this work
- **A. Gougelet**. Epigenetic modulation of immunity: towards new therapeutic avenues in hepatocellular carcinoma? **Gut.** 2019; 68 (10): 1727-1728. doi: 10.1136/gutjnl-2019-319084.
- **A. Gougelet** and C. Desbois-Mouthon. Non-coding RNAs Open a New Chapter in Liver Cancer Treatment. **Clin Res Hepatol Gastroenterol.** 2019, 43 (6): 630-637. 10.1016/j.clinre.2019.07.005
- **A. Gougelet**. Exosomal microRNAs as a potential therapeutic strategy in hepatocellular carcinoma. **World J Hepatol.** 2018; 10(11): 785-789. doi : 10.4254/wjh.v10.i11.785.
- **A. Gougelet**, C. Sartor, L. Bachelot, *et al.* Antitumor activity of an inhibitor of miR-34a in liver cancer mutated for β -catenin. **Gut.** 2016; 65:6 1024-1034. doi: 10.1136/gutjnl-2014-308969.
- Lechel A and **Gougelet A**. Early HCC treatment: a future strategy against interferon/miR-484 axis to revert precancerous lesions? **Gut.** 2016 Mar 4. 65: (7) 1073-1074. doi: 10.1136/gutjnl-2016-311446.
- **A. Gougelet**, C.Torre, P.Veber, *et al.* T-cell factor 4 and β -catenin chromatin occupancies pattern zonal liver metabolism. **Hepatology.** 2014 Jun; 59(6): 2344-57. doi: 10.1002/hep.26924.